The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

As the deputy editor who oversees Forbes Vetted’s beauty vertical, I rounded up the best teeth whitening kits based on recommendations from dentists and insights from five staff testers.

The winner of the R33 million Powerball jackpot bought their ticket using a banking app. The National Lottery confirmed on Wednesday afternoon that the Powerball Plus jackpot of R33,515,456.40 ...

Though unconfirmed by the club, Footy Headlines reports that Charlotte's new away kit for the 2025 season will feature black, replacing the purple used for the past two years. The design will ...

Meal kits and prepared meal delivery have changed weekday dinners for good. You don't have to run to the grocery store last minute or deal with the stress of figuring out what to make after a long ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.